Bedrijfsoverzicht
HeartSciences Inc. is a specialized medical technology enterprise dedicated to enhancing the clinical utility of electrocardiograms through the application of artificial intelligence. The company operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where it aims to develop AI-enhanced ECG solutions capable of detecting impaired cardiac relaxation or cardiac dysfunction. As of the latest reporting period, the entity maintains a market capitalization of $6.62M, generates annual revenue of $8,669, and employs a workforce of 15 individuals. These financial figures indicate that HeartSciences Inc. is a micro-cap entity operating with a significantly small revenue base relative to its market valuation, suggesting a high-risk profile typical of early-stage biotech or medical device firms that are still in the development or commercialization phase rather than established profitability.
Financiële gezondheid
The company reported a revenue of $8,669 for the trailing twelve months, yet it recorded a net income of $-8,485,301 and an EBITDA of $-7,768,315. The substantial disparity between the nominal revenue and the massive net loss reveals a highly leveraged cost structure where operating expenses, likely driven by research and development or commercialization efforts, far exceed income generation. Furthermore, the free cash flow stands at $-4,213,324, indicating that the company is burning cash rapidly, which severely limits its current financial flexibility and necessitates ongoing capital raising to sustain operations. Margin analysis shows a gross margin of 57.9%, suggesting that the core product or service retains significant value before overhead costs, while the operating margin of -89939.6% and profit margin of 0.0% highlight extreme inefficiencies or one-time costs that are distorting the bottom-line performance. On the balance sheet, the company holds $3.40M in cash against $3.87M in debt, resulting in a debt-to-equity ratio of 145.81, which characterizes the firm as highly leveraged and financially precarious given its inability to cover interest obligations from current earnings. The current ratio of 1.19 suggests a tight liquidity position where current assets barely cover current liabilities, leaving little room for error in meeting short-term financial obligations. Finally, the return on equity is -382.3% and the return on assets is -73.5%, metrics that demonstrate a severe failure in management effectiveness to generate positive returns on the capital invested by shareholders or utilized in asset deployment.
Waarderingsbeoordeling
Valuation metrics for HeartSciences Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at -0.74. The difference between these metrics, specifically the negative forward valuation, implies that the market expects earnings to remain negative in the near future, reflecting the high probability of continued losses without immediate profitability. The price-to-book ratio stands at 2.50, indicating that the market values the company at two and a half times its net book value, a premium often seen in speculative assets where future potential is priced in despite current financial unprofitability. Alternative valuation measures such as the price-to-sales ratio of 764.12 and an EV/EBITDA of -0.91 suggest that traditional multiples are not applicable, yet the extremely high P/S ratio indicates investors are paying a massive multiple for every dollar of sales, likely betting on a successful future commercialization of their AI-ECG technology. The stock trades between a 52-week high of $6.47 and a 52-week low of $2.01, and given the current market data points, the share price is currently positioned within this volatile range, reflecting the uncertainty surrounding the company's path to profitability. Additionally, the beta value of 2.45 indicates that the stock price is significantly more volatile than the broader market, moving with much greater intensity to news regarding clinical trials, regulatory approvals, or general sector sentiment.
Growth & Income
Regarding growth dynamics, the company exhibits a revenue growth year-over-year of N/A and an earnings growth year-over-year of N/A, as these figures cannot be calculated with consistent historical data for a company of this size or stage. Since there is no positive earnings growth to compare against revenue changes, the relationship between the two cannot be established in terms of efficiency, implying that the business is still finding its footing in the market. HeartSciences Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all of its limited earnings—or rather, its capital reserves—to fund operations and development rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for future expansion through reinvestment, with no current cash flow support for income generation, leaving the company reliant on external financing to fund its growth trajectory and navigate the challenges of the medical device industry.